Impact of a Clinical Pharmacist Stress Ulcer Prophylaxis Management Program on Inappropriate Use in Hospitalized Patients Mitchell S. Buckley, PharmD, Andrew S. Park, PharmD, Clint S. Anderson, PharmD, Jeffrey F. Barletta, PharmD, Dale S. Bikin, PharmD, Richard D. Gerkin, MD, Cheryl W. O'Malley, MD, Laura M. Wicks, PharmD, Roxanne Garcia-Orr, MD, Sandra L. Kane-Gill, PharmD, MSc The American Journal of Medicine Volume 128, Issue 8, Pages 905-913 (August 2015) DOI: 10.1016/j.amjmed.2015.02.014 Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 1 Flow chart of the number of patient-days and patients. AST = acid suppressive therapy; ICU = intensive care unit. The American Journal of Medicine 2015 128, 905-913DOI: (10.1016/j.amjmed.2015.02.014) Copyright © 2015 Elsevier Inc. Terms and Conditions
Figure 2 Inappropriate stress ulcer prophylaxis continuation upon hospital discharge rates. ICU = intensive care unit. The American Journal of Medicine 2015 128, 905-913DOI: (10.1016/j.amjmed.2015.02.014) Copyright © 2015 Elsevier Inc. Terms and Conditions